Chenghe Acquisition Co. priced its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “CHEAU” Thursday, April 28, 2022.
The new SPAC intends to focus on financial technology or technology-enabled financial service companies, including artificial intelligence, big data, cloud and blockchain-related initiatives in Asian markets. Chenghe is led by Chairman Richard Qi Li, CEO Shibin Wang, and CFO Anna Zhou.
Total SPAC deal count for 2022 year-to-date is now 61. This offering is expected to close on Monday, May 2.
Morgan Stanley & Co. LLC and EarlyBirdCapital, Inc. are acting as joint book-running managers for the offering, and Revere Securities LLC is acting as co-manager. White & Case LLP is serving as Issuer’s Counsel with Paul Hastings LLP serving as Underwriter’s Counsel. Marcum Bernstein & Pinchuk LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....
1RT Acquisition Corp. (NASDAQ:ONCHU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ONCHU”, Wednesday, July 2, 2025. The new SPAC plans to target company in the digital asset ecosystem involved in the creation, storage, exchange or management of such assets, whether...
D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...